1. 1.‎ Stoelting RK, Dierdorf SF. Anesthesia and co-existing disease. 2002.‎ ‎2.‎ Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., ‎Ho, M., Howard, V., Kissela, B., Kittner, S., Lloyd-Jones, D., McDermott, M., Meigs, J., ‎Moy, C., Nichol, G., O'Donnell, C., Roger, V., Sorlie, P., Steinberger, J., … American ‎Heart Association Statistics Committee and Stroke Statistics Subcommittee (2008). ‎Heart disease and stroke statistics--2008 update: a report from the American Heart ‎Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, ‎‎117(4), e25–e146. https://doi.org/10.1161/CIRCULATIONAHA.107.187998‎ ‎3.‎ Shafiei Z, Babaee S, Nazari A. Relationship between Mood State and Quality of Life in ‎Patients Undergoing Coronary Artery Bypass Graft Surgery. IJN. 2013; 26 (83) :57-67. ‎URL: http://ijn.iums.ac.ir/article-1-1611-en.html ‎4.‎ Shafiei Z, Babaee S, Nazari A. Relationship between Mood State and Quality of Life in ‎Patients Undergoing Coronary Artery Bypass Graft Surgery. IJN. 2013; 26 (83) :57-67. ‎URL: http://ijn.iums.ac.ir/article-1-1611-en.html ‎5.‎ Mojahed A, Bazi M, Azadi Ahmadabadi C, Abbasi Mendi A, Shahraki N. Comparisons ‎of patients’ quality of life before and after coronary artery bypass graft surgery in Ali ‎Ibn Abi Talib Hospital in Zahedan in 2016. RJMS. 2018; 25 (3) :1-9. URL: ‎http://rjms.iums.ac.ir/article-1-4932-en.html ‎6.‎ Babaee G, Keshavarz M, Shayegan AH. Effect of a health education program on quality ‎of life in patients undergoing coronary artery bypass surgery. Acta Medica Iranica. ‎‎2007:69-75.‎ ‎7.‎ MontazerGhaem S, Asar O, Safaei N. Assessing patientś quality of life after open hart ‎surgery in Bandar Abbass, Iran. Hormozgan Med J 2012;15(4):254-9.‎ ‎8.‎ Newcomb AE, Dignan R, McElduff P, Pearse EJ, Bannon P. Bleeding after cardiac ‎surgery is associated with an increase in the total cost of the hospital stay. The Annals ‎of thoracic surgery. 2020 Apr 1; 109(4):1069-78. DOI: 10.1016/j.athoracsur.2019.11.019‎ ‎9.‎ Fassin W, Himpe D, Alexander JP, Borms S, Theunissen W, Muylaert P, Van ‎Cauwelaert P. Predictive value of coagulation testing in cardiopulmonary bypass ‎surgery. Acta Anaesthesiologica Belgica. 1991 Jan 1; 42(4):191-8.‎ ‎10.‎ Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic ‎effects of aprotinin, tranexamic acid and ϵ-aminocaproic acid in primary cardiac ‎surgery. The Annals of thoracic surgery. 1999 Dec 1; 68(6):2252-6. DOI: ‎‎10.1016/s0003-4975(99)00866-8‎ ‎11.‎ Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber SM, Geissler HJ, Mehlhorn ‎U. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements ‎after cardiopulmonary bypass: a prospective, randomised, double-blind trial. Current ‎medical research and opinion. 2004 Jan 1;20(1):121-6. DOI: ‎‎10.1185/030079903125002658.‎ ‎12.‎ Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postoperative ‎bleeding and related hematochemical variables in coronary surgery: Comparison ‎between on-pump and off-pump techniques. J Thorac Cardiovasc Surg. 2004;128(1):83-‎‎91. doi:10.1016/j.jtcvs.2003.10.034‎ ‎13.‎ Cai J, Ribkoff J, Olson S, et al. The many roles of tranexamic acid: An overview of the ‎clinical indications for TXA in medical and surgical patients. Eur J Haematol. ‎‎2020;104(2):79-87. doi:10.1111/ejh.13348‎ ‎14.‎ Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul ‎Fibrinolysis. 2004;15 Suppl 1:S31-S32. doi:10.1097/00001721-200405001-00007‎ ‎15.‎ Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive ‎blood loss with mortality in cardiac surgery. Transfusion. 2004;44(10):1453-1462. ‎doi:10.1111/j.1537-2995.2004.04144.x‎ ‎16.‎ Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison ‎of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. ‎‎2006;46(3):327-338. doi:10.1111/j.1537-2995.2006.00724.x‎ ‎17.‎ Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Ståhle E, Dawkins KD, ‎Mohr FW, Serruys PW, Colombo A. Comparison of coronary bypass surgery with drug-‎eluting stenting for the treatment of left main and/or three-vessel disease: 3-year ‎follow-up of the SYNTAX trial. Eur Heart J. 2011 Sep;32(17):2125-34. doi: ‎‎10.1093/eurheartj/ehr213.‎ ‎18.‎ Flegel WA, Natanson C, Klein HG. Does prolonged storage of red blood cells cause ‎harm?. Br J Haematol. 2014;165(1):3-16. doi:10.1111/bjh.12747‎ ‎19.‎ Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in ‎coronary artery bypass graft surgery. JAMA. 2010;304(14):1568-1575. ‎doi:10.1001/jama.2010.1406‎ ‎20.‎ Fitzgerald DC, Simpson AN, Baker RA, et al. Determinants of hospital variability in ‎perioperative red blood cell transfusions during coronary artery bypass graft surgery ‎‎[published online ahead of print, 2020 May 13]. J Thorac Cardiovasc Surg. 2020;S0022-‎‎5223(20)31128-4. doi:10.1016/j.jtcvs.2020.04.141‎ ‎21.‎ Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, ‎Silverman A, Park M, Valeri CR. Hematologic changes during and after ‎cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical ‎blood loss. The journal of Thoracic and cardiovascular surgery. 1992 Jul 1;104(1):94-‎‎107.‎ ‎22.‎ Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D. Differential redistribution of ‎platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation [published erratum ‎appears in Blood 1991 Jul 15; 78 (2): 545].‎ ‎23.‎ Fullerton D, Grover F. Surgery of the chest. 6 th Ed. Toronto. Saunders Company. 1996; ‎pp: 1884-1897.‎ ‎24.‎ Branchereau A. Glenn's Thoracic and Cardiovascular Surgery. 6th Edn.‎ ‎25.‎ Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising ‎perioperative allogeneic blood transfusion. The Cochrane Database of Systematic ‎Reviews. 2011 Jan(1):CD001886. DOI: 10.1002/14651858.cd001886.‎ ‎26.‎ Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in current anaesthetic ‎practice. British journal of anaesthesia. 2013 Oct 1;111(4):549-63. ‎https://doi.org/10.1093/bja/aet154‎ ‎27.‎ Santos AT, Kalil RA, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-‎blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic ‎activity after primary coronary artery bypass grafting. Brazilian journal of medical and ‎biological research. 2006 Jan;39(1):63-9.‎ ‎28.‎ Kohno K, Kimura S, Kashima T, Kume M, Hirata I, Amano H, Iwasa S, Meguro T, ‎Fukaya T. Hemostatic effect of tranexamic acid (transamin) during coronary artery ‎bypass grafting. Journal of Artificial Organs. 2001 Sep;4(3):241-4.‎ ‎29.‎ Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and ‎adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007 Jun ‎‎5;115(22):2801-13.‎ ‎30.‎ Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective, primary coronary ‎artery bypass surgery using cardiopulmonary bypass. Eur J Cardiothorac Surg. ‎‎2004;26(2):311-317. doi:10.1016/j.ejcts.2004.03.012‎ ‎31.‎ Ghavidel AA, Jalilifar N, Sharifi M, Ghasemzadeh B, Alinejad Z, Ghafarinejad MH, ‎Khamushi A, Bakhshande H, Hosseini S, Farsad F, Yousefnia MA. Role of Epsilon ‎Aminocaproic acid & Tranexamic Acid, vs Placebo in Reduction of mediastinal ‎Bleeding following Open Heart Surgery.‎ ‎32.‎ Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing ‎Coronary-Artery Surgery [published correction appears in N Engl J Med. 2018 Feb ‎‎22;378(8):782]. N Engl J Med. 2017;376(2):136-148. doi:10.1056/NEJMoa1606424‎ ‎33.‎ Yao YT, He LX, Tan JC. The effect of tranexamic acid on the values of activated ‎clotting time in patients undergoing cardiac surgery: A PRISMA-compliant systematic ‎review and meta-analysis. J Clin Anesth. 2020;67:110020. ‎doi:10.1016/j.jclinane.2020.110020‎ ‎34.‎ Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial ‎and economic evaluation of the effects of tranexamic acid on death, vascular occlusive ‎events and transfusion requirement in bleeding trauma patients. Health Technol Assess. ‎‎2013;17(10):1-79. doi:10.3310/hta17100‎ ‎35.‎ Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A ‎double-blind trial. Br Med J. 1970;4(5729):214-216. doi:10.1136/bmj.4.5729.214‎ ‎36.‎ Ozier Y, Schlumberger S. Pharmacological approaches to reducing blood loss and ‎transfusions in the surgical patient. Can J Anaesth. 2006;53(6 Suppl):S21-S29. ‎doi:10.1007/BF03022249‎ ‎37.‎ Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic ‎drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. ‎‎2018;2(2):CD012964. Published 2018 Feb 20. doi:10.1002/14651858.CD012964‎ ‎38.‎ Sentilhes L, Winer N, Azria E, et al. Tranexamic Acid for the Prevention of Blood Loss ‎after Vaginal Delivery. N Engl J Med. 2018;379(8):731-742. ‎doi:10.1056/NEJMoa1800942‎ ‎39.‎ McCormack PL. Tranexamic acid: a review of its use in the treatment of ‎hyperfibrinolysis. Drugs. 2012;72(5):585-617. doi:10.2165/11209070-000000000-00000‎ ‎40.‎ Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces ‎fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg. 1995;60(4):1008-1014. ‎doi:10.1016/0003-4975(95)00668-b ‎41.‎ Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol ‎Intensive Ther. 2015;47(4):339-350. doi:10.5603/AIT.a2015.0011‎ ‎42.‎ Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during ‎extracorporeal circulation. American journal of hematology. 1991 Oct;38(2):113-9.‎ ‎43.‎ Jimenez JJ, Iribarren JL, Lorente L, et al. Tranexamic acid attenuates inflammatory ‎response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case ‎control study followed by a randomized double-blind controlled trial. Crit Care. ‎‎2007;11(6):R117. doi:10.1186/cc6173‎ ‎44.‎ Schöchl H, Frietsch T, Pavelka M, Jámbor C. Hyperfibrinolysis after major trauma: ‎differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J ‎Trauma. 2009;67(1):125-131. doi:10.1097/TA.0b013e31818b2483‎ ‎45.‎ Ozal E, Kuralay E, Bingöl H, Cingöz F, Ceylan S, Tatar H. Does tranexamic acid reduce ‎desmopressin-induced hyperfibrinolysis?. J Thorac Cardiovasc Surg. 2002;123(3):539-‎‎543. doi:10.1067/mtc.2002.117281‎ ‎46.‎ Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose-‎response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. ‎Am J Obstet Gynecol. 2011;205(4):319.e1-319.e3197. doi:10.1016/j.ajog.2011.05.015‎ ‎47.‎ Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia ‎Research Group; Ischemia Research and Education Foundation. The risk associated with ‎aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353-365. ‎doi:10.1056/NEJMoa051379‎ ‎48.‎ Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical ‎bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. ‎Published 2012 May 17. doi:10.1136/bmj.e3054‎ ‎49.‎ Giordano R, Palma G, Poli V, et al. Tranexamic acid therapy in pediatric cardiac ‎surgery: a single-center study. Ann Thorac Surg. 2012;94(4):1302-1306. ‎doi:10.1016/j.athoracsur.2012.04.078‎ ‎50.‎ Giordano R, Palma G, Poli V, et al. Tranexamic acid therapy in pediatric cardiac ‎surgery: a single-center study. Ann Thorac Surg. 2012;94(4):1302-1306. ‎doi:10.1016/j.athoracsur.2012.04.078‎ ‎51.‎ Basta MN, Stricker PA, Taylor JA. A systematic review of the use of antifibrinolytic ‎agents in pediatric surgery and implications for craniofacial use. Pediatr Surg Int. ‎‎2012;28(11):1059-1069. doi:10.1007/s00383-012-3167-6‎ ‎52.‎ Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of ‎antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: ‎a systematic review of randomized trials. Thromb Res. 2009;123(5):687-696. ‎doi:10.1016/j.thromres.2008.09.015‎ ‎53.‎ Poeran J, Rasul R, Suzuki S, et al. Tranexamic acid use and postoperative outcomes in ‎patients undergoing total hip or knee arthroplasty in the United States: retrospective ‎analysis of effectiveness and safety. BMJ. 2014;349:g4829. Published 2014 Aug 12. ‎doi:10.1136/bmj.g4829‎ ‎54.‎ Zhang Y, Fu X, Liu WX, Li YM, Ma XL, Li ZJ. Safety and efficacy of intra-articular ‎injection of tranexamic acid in total knee arthroplasty. Orthopedics. 2014;37(9):e775-‎e782. doi:10.3928/01477447-20140825-53‎ ‎55.‎ CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on ‎death, vascular occlusive events, and blood transfusion in trauma patients with ‎significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. ‎‎2010;376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5‎ ‎56.‎ CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment ‎with tranexamic acid in bleeding trauma patients: an exploratory analysis of the ‎CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101.e11012. ‎doi:10.1016/S0140-6736(11)60278-X ‎57.‎ Armellin G, Vinciguerra A, Bonato R, Pittarello D, Giron GP. Tranexamic acid in ‎primary CABG surgery: high vs low dose. Minerva Anestesiol. 2004;70(3):97-107. ‎ ‎58.‎ Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual ‎bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865-875. ‎doi:10.1097/AOG.0b013e3181f20177‎ ‎59.‎ Weeks A. The prevention and treatment of postpartum haemorrhage: what do we know, ‎and where do we go to next?. BJOG. 2015;122(2):202-210. doi:10.1111/1471-‎‎0528.13098‎ ‎60.‎ Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum ‎haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. ‎‎2008;22(6):999-1012. doi:10.1016/j.bpobgyn.2008.08.004‎ ‎61.‎ Perel P, Ker K, Morales Uribe CH, Roberts I. Tranexamic acid for reducing mortality in ‎emergency and ‎62.‎ urgent surgery. Cochrane Database of Systematic Reviews 2012 , Issue 11 . Art. No.: ‎CD010245. DOI:10.1002/14651858.CD010245 .‎ ‎63.‎ Chornenki NLJ, Um KJ, Mendoza PA, et al. Risk of venous and arterial thrombosis in ‎non-surgical patients receiving systemic tranexamic acid: A systematic review and ‎meta-analysis. Thromb Res. 2019;179:81-86. doi:10.1016/j.thromres.2019.05.003‎ ‎64.‎ Goobie SM, Meier PM, Sethna NF, et al. Population pharmacokinetics of tranexamic ‎acid in paediatric patients undergoing craniosynostosis surgery. Clin Pharmacokinet. ‎‎2013;52(4):267-276. doi:10.1007/s40262-013-0033-1‎ ‎65.‎ Yee BE, Wissler RN, Zanghi CN, Feng C, Eaton MP. The effective concentration of ‎tranexamic acid for inhibition of fibrinolysis in neonatal plasma in vitro. Anesth Analg. ‎‎2013;117(4):767-772. doi:10.1213/ANE.0b013e3182a22258‎ ‎66.‎ Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total ‎knee replacement: a systematic review and meta-analysis. Knee. 2013;20(5):300-309. ‎doi:10.1016/j.knee.2013.05.014‎ ‎67.‎ Kaabachi O, Eddhif M, Rais K, Zaabar MA. Inadvertent intrathecal injection of ‎tranexamic acid. Saudi J Anaesth. 2011;5(1):90-92. doi:10.4103/1658-354X.76504‎ ‎68.‎ Manji RA, Grocott HP, Leake J, et al. Seizures following cardiac surgery: the impact of ‎tranexamic acid and other risk factors. Can J Anaesth. 2012;59(1):6-13. ‎doi:10.1007/s12630-011-9618-z ‎69.‎ Sharma V, Katznelson R, Jerath A, et al. The association between tranexamic acid and ‎convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. ‎Anaesthesia. 2014;69(2):124-130. doi:10.1111/anae.12516‎ ‎70.‎ Fiechtner BK, Nuttall GA, Johnson ME, et al. Plasma tranexamic acid concentrations ‎during cardiopulmonary bypass. Anesth Analg. 2001;92(5):1131-1136. ‎doi:10.1097/00000539-200105000-00010‎ ‎71.‎ Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during ‎cardiopulmonary bypass. Anesthesiology. 2002;97(2):390-399. doi:10.1097/00000542-‎‎200208000-00016‎ ‎72.‎ Negargar S, Naghipour B, Anvari S, Enamzadeh E, Shiriza-Deh M. EFFECTS OF PRE ‎AND POST-PUMP TRANEXAMIC ACID ON BLEEDING AFTER CORONARY ‎ARTERY BYPASS GRAFT SURGERY. ACTA MEDICA MEDITERRANEA. 2016 Jan ‎‎1;32:1231-5.‎ ‎73.‎ Gerstein NS, Deriy L, Patel PA. Tranexamic Acid Use in Cardiac Surgery: Hemostasis, ‎Seizures, or a Little of Both. J Cardiothorac Vasc Anesth. 2018;32(4):1635-1637. ‎doi:10.1053/j.jvca.2017.12.001‎ ‎74.‎ Besser V, Albert A, Sixt SU, et al. Fibrinolysis and the Influence of Tranexamic Acid ‎Dosing in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2020;34(10):2664-2673. ‎doi:10.1053/j.jvca.2020.03.040‎ ‎75.‎ Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ. Drugs to reduce ‎bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and ‎network meta‐analysis. The Cochrane Database of Systematic Reviews. 2019 ‎Sep;2019(9). doi: 10.1002/14651858.CD013649‎ ‎76.‎ Yang JM, Zhang C, Li CB, Huang GW, Yu DF. Tranexamic acid application in open ‎heart valve replacement surgery. Chin J Mod Ope Sur 2017;21(02):117–20.‎